Who are QM1114-DP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sohonos, Panretin, Targretin, Differin, Tegison, Accutane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qm1114-dp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

QM1114-DP — Competitive Intelligence Brief

QM1114-DP (QM1114-DP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: topical retinoid. Area: Dermatology.

phase 3 topical retinoid retinoic acid receptor Dermatology Biologic Live · refreshed every 30 min

Target snapshot

QM1114-DP (QM1114-DP) — Galderma R&D. QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
QM1114-DP TARGET	QM1114-DP	Galderma R&D	phase 3	topical retinoid	retinoic acid receptor
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Targretin	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01
Tegison	ETRETINATE		marketed	Retinoid	Retinoic acid receptor RXR-gamma	1986-01-01
Accutane	ISOTRETINOIN		marketed	Retinoid [EPC]	Retinoic acid receptor alpha	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-09-15 — Differin · 8435502 · Formulation · US
2026-09-15 — Differin · 8709392 · Formulation · US
2028-05-31 — Differin · 7998467 · Formulation · US
2035-05-29 — Accutane · 9750711 · Formulation · US
2035-08-04 — Accutane · 9700535 · Formulation · US

Sponsor landscape (topical retinoid class)

Galderma R&D · 2 drugs in this class
Medicis Global Service Corporation · 1 drug in this class
Sol-Gel Technologies, Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QM1114-DP — Competitive Intelligence Brief. https://druglandscape.com/ci/qm1114-dp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab